



SPAFID
CONNECT

Informazione Regolamentata n. 20106-34-2022	Data/Ora Ricezione 02 Maggio 2022 12:20:38	Euronext Star Milan
---	--	---------------------

Societa' : PHARMANUTRA
Identificativo : 161392
Informazione
Regolamentata
Nome utilizzatore : PHARMANUTRAN04 - Roberto Lacorte
Tipologia : REGEM
Data/Ora Ricezione : 02 Maggio 2022 12:20:38
Data/Ora Inizio : 02 Maggio 2022 12:20:39
Diffusione presunta
Oggetto : PHARMANUTRA_PR Synthetic report on
voting results

Testo del comunicato

Vedi allegato.

PHARMANUTRA S.P.A.: SYNTHETIC REPORT ON VOTING RESULTS ON AGENDA ITEMS OF THE ORDINARY SHAREHOLDERS' MEETINGS HELD ON APRIL 27, 2022

Pisa, 2nd May 2022 – [PharmaNutra S.p.A.](https://www.pharmanutra.it) (MTA; Ticker PHN) informs that the Synthetic Report on voting results on agenda items of the Ordinary Shareholders' Meeting held on 27 April 2022 is available on the website at www.pharmanutra.it (section Governance/Shareholders' Meetings).

PharmaNutra S.p.A.

Founded and led by the President Andrea Lacorte and Vice President Roberto Lacorte, PharmaNutra was established in 2003. It develops unique nutritional supplements and innovative nutritional devices, handling the entire production process, from proprietary raw materials to finished product. The effectiveness of its products is documented by more than 135 scientific studies. The Group distributes and sells its products in Italy and abroad. In Italy, products are sold through a network of approximately 150 Pharmaceutical Representatives serving doctors and exclusively selling PharmaNutra products to pharmacies throughout Italy. Products are sold in 60 countries abroad, through 41 partners selected from among the finest pharmaceutical companies. Over the years, PharmaNutra has stood out in the production of iron-based nutritional supplements with the trademark SiderAL®, where it can claim important Sucrosomial Technology® patents. The Group has developed a precise strategy for the management and production of intellectual property, founded on the integrated management of all the various elements: proprietary raw materials, patents, brands and clinical evidence.

[PharmaNutra.it](https://www.pharmanutra.it)

For further information:

PharmaNutra S.p.A.

Via Delle Lenze, 216/b - 56122 Pisa

Tel. +39 050 7846500

investorrelation@PharmaNutra.it

Internal Press Office

press@calabughi.com

Press Office - Spriano Communication & Partners

Via Santa Radegonda, 16 - 20121 Milan

Tel. +39 02 83635708

Matteo Russo

mrusso@sprianocommunication.com

Cristina Tronconi

ctronconi@sprianocommunication.com

Fine Comunicato n.20106-34

Numero di Pagine: 3